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Snakebite envenomation constitutes to be a major public health problem in the most resource 
poor, tropical areas of the world, resulting in death or severe sequelae. Snakebites were 
officially included in the Neglected Tropical Disease portfolio of the World Health Organization in 
2018, after the World Health Assembly acknowledged it as a Global Health problem. This study 
details the journey of snakebites from obscurity to its inclusion in Global Health agenda over the 
course of the twentieth and twenty first century and argues that the main thrust of the movement 
came from South-to-South partnerships between academic and public-private research 
institutions. It explores how Latin American countries, such as Costa Rica and Brazil, played 
crucial roles in promoting the international movement of snakebites, challenging the paradigm 
that scientific and pharmacological knowledge and objects only emerge from the Global North 
and flow to the Global South, and provides evidence of scientific excellence at the periphery.  
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“Few subjects have stimulated the minds and imagination of man more than the study of snakes 
and snake venoms. No animal has been more worshipped yet more cast out, more loved yet 
more despised, more envied yet more caged, and more collected yet more trampled upon than 
the snake.” 
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Snakebite envenoming is a life-threatening condition that is prevalent in the most 
resource poor settings of the world. Approximately 412,000 to 1.2 million cases of snakebites 
and 81,000 to 138,000 associated deaths a year are estimated to occur, according to estimates 
from the World Health Organization(1, 2). This is a disease that has been prevalent for 
millennia, yet only in the second decade of the 21st century did it entered the Global Health 
agenda as a result of its inclusion as a Neglected Tropical Diseases during the tenth World 
Health Organization strategic and technical advisory group (STAG) for Neglected Tropical 
Diseases (NTDs) meeting that took place on March 29-30 2017, and the subsequent resolution 
(WHA71.5) of the of the 71st World Health Assembly that took place on May 24, 2018 (3, 4). 
Resolution WHA71.5 acknowledge the worldwide neglect of snakebites as an important 
public health issue, and made access to effective, affordable, and safe antivenin a priority. The 
resolution also recommended the creation of partnerships and international cooperation that 
would enable the attainment of these goals, through the efficient evaluation of the burden of 
snakebites in low- and middle-income countries, as well as the technological transfer of 
antivenin production technologies to areas of the world were the burden is greatest (4).  
Snakebites was one of the latest additions to the NTD portfolio, which currently holds 20 
diseases, most of which are caused by parasitic pathogens that disproportionately affect people 
living in the poorest nations of the world.  Strikingly, snakebites are differentiated from the rest 
of the NTD portfolio because envenomation is not a disease caused by a pathogen, but by the 
toxicological and physio pathological effect of venom introduced to the body by the bite of a 
venomous snake. Additionally, there is no one single universal solution for snakebite 
envenomation. On the contrary, antivenom is specific to the snake genus. As a result, 
antivenom production needs to be tailored towards the territorial distribution of venomous 
snakes and incidence of envenomation cases. The lack of resemblance of snakebites with other 
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NTDs was highlighted in the report of the tenth meeting of the WHO STAG for NTDs held in 
Geneva in 2017. The STAG agreed that WHO should address the issue but it was “unsure that 
the programmatic aspects of this would be best handled by the NTD Department” (3). 
How did snakebites become a Neglected Tropical Disease? In this essay, we will 
explore the main forces, actors and events that led to the transition of snakebites from obscurity 
to its inclusion in the NTD portfolio of the World Health Organization. We argue that the main 
efforts that lead to this crucial step was driven by multiple South-to-South international coalitions 
and partnerships, with South American countries playing key roles in this quest. This study will 
challenge the traditional view that scientific advances in Global Health emerge from the 
scientific and technological hubs of the Global North, and unidirectionally flow to the receptive 
peripheries of the Global South. To explore this argument, this study will provide a detailed view 
of the process by which the public health problem of snakebites became recognized as a Global 
Health problem. Specifically, we will examine the first steps in snakebite research, antivenom 
production and inter-institutional collaboration among four key countries in the early twentieth 
century: Costa Rica, Brazil, and the United States. This review will enable us to understand the 
social, political, and economic factors that led to the emergence of early snakebite research and 
that helped foster later international collaborations. Next, it will examine how key South 
American countries, serving as champions of snakebite research and advocacy, created South 
to South public-private partnerships that helped catapult the problem of snakebites into the NTD 
portfolio of WHO. Finally, it will explore the current challenges facing efforts to keep snakebites 
in the NTD portfolio. We will contextualize and seek to explain these developments through a 
framework that focuses on the history of science in Latin America. In doing so, the paper will 
utilize the concept of “peripheral science” and “science at the periphery”, concepts that has 




Background: Global Burden and Key Challenges in Snakebite Control 
In 1954, the World Health organization requested a study to evaluate the importance 
snakebite mortality worldwide. S. Swaroop, as chief of the Statistical Studies Section of WHO, 
was commission to conduct this study (7). In Swaroop’s report it was estimated that at least 
30,000 to 40,000 deaths occurred per year. Yet The New England Journal of Medicine 
acknowledged that same year that the recording and reporting of snakebite deaths was 
“obviously handicapped by the fact that registration of deaths in general is inadequate”(8). 
Unfortunately, this is still the case in the 21st century, as set forth both by J.P. Chippaux’s 
appraisal of the global situation of snakebites, and a modelling effort by a group of researchers 
from the University of Kelaniya in Sri Lanka, the WHO department of Control of NTDs and the 
Liverpool School of Tropical Medicine in the United Kingdom(2). In the latter, researchers 
performed a meta-analysis for which they were able to extract reliable data from only 160 
publications from 68 countries (1). The majority of cases were estimated to occur in South East 
Asia (18.82-84.65 cases per 100,000 people year), followed by Central Sub Saharan Africa 
(20.28 – 53.37 cases per 100,00 people a year), and Central Latin America (12.90 -54.47 cases 
per 100,000 people a year) (1). Jean Phillippe Chippaux and Jose Maria Gutierrez argued that 
the lack of primary data on the burden of snakebites at a national level resulted from patients 
not reaching primary health centers or hospitals once injured or doing so with substantial 
delay(9, 10). The sequalae and morbidity associated with snakebites was presumed to be 
further underestimated because of case underreporting, low rates of attendance to the health 
centers, and the absence of traditional healing information(10). The delay in reaching health 
centers in rural areas of the world was further highlighted by modeling estimates done by 
Joshua Longbottom and collaborators. Longbottom estimated that 11.0% of people living with a 
risk of high exposure to venomous snakes lived more than 1 hour away from an urban center 
(and thus a health care center). Additionally, 65.3% of people with access to the lowest quality 
of care (as catalogued by Healthcare Access and Quality (HAQ) Index) were at risk of exposure 
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to venomous snakes for which there was no known antivenom, in comparison to only 29.8% of 
people with access to the highest quality of care. Strikingly, antivenom was not available for 
more than 57% of known venomous snakes (11). 
The production, distribution, and access to antivenom in isolated and at-risk areas for 
venomous snake exposure was the most critical need to tackle this disease. This was termed 
the antivenom crisis and was the catalyst of working and analysis groups that have attempted 
(unsuccessfully) to resolve it (12). Several obstacles have blocked progress over the decades. 
The first, and perhaps the most critical one, was the lack of antivenom production at a local 
level, a problem which was associated with scant research and development of new production 
techniques that were able to go through an efficient technological transfer process (13).  
The commercial production and distribution of snake antivenin in Latin America (and the 
world) was initiated in the early twentieth century, with Brazil as a pioneer in research, 
development, and technological transfer. These early Latin American collaborative efforts 
formed the foundation for efforts to move snakebites onto the Global Health agenda. It is 
important to highlight that collaborations between South American countries, or between South 
American, Asian and African countries were the result of scientific work produced within each 
nation’s own history of scientific development, and that were influenced by national and regional 
sociopolitical, cultural, and economic developments. As a result, it is important to frame these 
collaborations within each country individual microcosm of scientific development, as well as 




Brief Overview of the History of Neglected Tropical Diseases 
Dr. Kenneth S. Warren, the head of the Rockefeller Foundation launched in 1977 the 
“Great Neglected Diseases of Mankind Program” (GND) an international effort to study parasitic 
diseases that were being mostly ignored by academic scientists of United States and Europe 
(14, 15). As a parasitologist himself, Warren and the GND program predominantly focused on 
the study of parasitic diseases of the tropics, such as Schistosomiasis, Filariasis, 
Trypanosomiasis, Onchocerciasis and Hookworm. Warren aimed to modernize the field of 
parasitology by bridging the gap between parasitology and the evolving field of molecular 
biology (14). As Conrad Keating described, over the eight years the program existed, it trained 
over 360 individuals (150 from the Global South) and produced over 180 scientific publication 
on parasitic diseases of the developing world, revolutionizing the field of parasitology, and 
global health research as a whole (14). Warren classified these parasitic diseases as incredibly 
common, globally distributed, yet largely forgotten by Western medicine. Warren conceptualized 
these diseases as a numerical problem, which low-cost interventions at a population scale 
would be able to control. In fact, Warren was critical WHOs focus on building primary health 
care services, following on the 1978 Alma Atta declaration, and advocated the use of  more 
targeted health interventions that could “maximize improvement of health and medical care in 
less developed countries”(16).  
A concomitant effort to tackle unattended diseases of the poorest was the creation of the 
Special Program for Research and Training in Tropical Diseases by the World Health 
Organization in 1977, financially supported by the United Nations Development Program and 
the World Bank(17, 18). The program aimed to improve the control of six tropical diseases 
(Malaria, Schistosomiasis, Filariasis, African trypanosomiasis, Chagas diseases, Leishmaniasis 
and Leprosy) by increasing the research capacity of countries with a high burden of disease and 
promoting research and the development of new tools for controlling these diseases(19).   
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The push for global health recognition of neglected tropical disease was accelerated by 
the incorporation of multinational pharmaceutical companies as major suppliers of low cost 
antiparasitic and antibacterial drugs. Antiparasitic drugs, like Ivermectin, albendazole, 
mebendazole, praziquantel and azithromycin produced by Merck, GlaxoSmithKline, MSD and 
Pfizer markedly changed the prospects for controlling neglected tropical disease. By agreeing to 
donate these drugs for mass-administration campaigns, multinational pharmaceutical 
corporations became important partners in the push to place neglected tropical disease onto the 
global health agenda. It is worth noting that many of the new drugs had little commercial value 
for the pharmaceuticals, yet their participation as benefactors of the Global South directly 
benefited them through tax deductions, as well as by improving their global institutional image.  
 In December 2003 the World Health Organization met in Berlin for the first time with the 
German Corporation for International Cooperation (GTZ) and established a collaborative and 
collective effort to combat neglected tropical diseases(20). The meeting produced the first 
conceptual framework by the agency in which the need to tackle these diseases using a holistic 
approach was emphasized. This meant that the disease should be tackled on various fronts and 
under a coordinated approach, through a variety of mechanisms. These could include research 
and development, improved health care access and delivery, health care capacity building and 
enactment of policies that would facilitate the implementation of programs. Additionally, these 
programs were supposed to undertake a horizontal approach to disease control, involving not 
only the academic institutions, but also health care facilities, private companies, non-
governmental organizations, grass-roots organizations, and the general public at large.  In 
addition, the link between NTDs, poverty and development was finally agreed upon and 
established so that controlling NTDS became viewed as an important step towards achieving 
the Millennium Development Goals(21).  
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In a second meeting in April 2005 (Berlin II), the World Health Organization in alliance 
with the German Ministry of Health, the German Ministry of Economic Cooperation, German 
Corporation for International Cooperation (GTZ), the Kreditanstalt für Wiederaufbau (KFW) 
development bank, and the WHO Special Program for Research and Training in Tropical 
Diseases (TDR) met again in Berlin to discuss the strategic and technical aspects of escalating 
the control of neglected tropical diseases(21). Three approaches were highlighted in their 
report: 1) the use of rapid-impact interventions, 2) increased vector control to decrease 
transmission, and 3) improved surveillance and high-quality care. The underlying intervention 
promoting these approaches was the population level implementation of mass drug 
administration programs though an integrative framework, rather than through a clinical 
approach. The report highlighted the need for establishing “long-term linkages” across programs 
to ensure the overall success of the strategy. A direct result of this meeting was the creation of 
the WHO department of Neglected Tropical Diseases in 2005 with Dr. Lorenzo Savioli as its 
founding director. The main goal of the department was the translation of research and 
advocacy into global health policy for the prevention and control of 17 NTDs. The Global Plan to 
Combat Neglected Tropical Diseases: 2008-2015 was published in 2007(22). However, it was 
not until 2013 that WHO member states endorsed the resolutions for the proposed NTDs and 
confirmed the political will by signing countries to their prevention and control (66.12 World 
Health Assembly Resolutions on Neglected Tropical Diseases: 1948-2019).  
The diseases included in the First WHO report on Neglected Tropical Diseases were 
Dengue, Rabies, Trachoma, Buruli ulcer, Leprosy, Chagas disease, Human African 
trypanosomiasis, Leishmaniasis, Cysticercosis, Dracunculiasis, Echinococcosis, Foodborne 
trematode infections (Fascioliasis), Lymphatic filariasis, Onchocerciasis, Schistosomiasis, Soil-
transmitted helminthiasis and Yaws(23).  
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Snakebites clearly did not fit the model of a neglected tropical disease that had been 
built between the 1970s and early 2000s. Antivenin could be considered a rapid-impact 
intervention. However, there was not a single antivenin that could be efficiently used globally, 
due to the specific nature and toxicological effects of snake venom. Vector control did not apply 
to snakebites unless one considered the reptile itself as the vector of the venom. That said, the 
incidence of human-snake encounters, like that of NTDs, was highest at the interphase with 
wildlife, such as subsistence farming and agricultural areas in the tropics.  
Yet in other ways, snakebite control strategies that were used by institutions working in 
Latin America to help tackle this issue were compatible with the holistic framework of action 
required by the NTDs program. First, it called for a coordinated approach focused on treatment 
access and improved health care delivery at a marginal cost compared to the morbidity and 
overall loss of human potential associated with the disease. Secondly, like other NTDs 
snakebite strategies required a coordinated action and collaboration with pharmaceutical 
companies, which is an active area of work of the department of NTDs. Finally, snakebites 
required a “multi-facetted holistic” approach to control this complex problem at a global scale. 
The challenge for snakebite advocates was to make this case to the WHO.  
Snakebite Antivenin Production in Latin America: Key players  
Snakebites were not originally considered a neglected tropical disease. This was a result 
of the initial concept and framework under which NTDs were classified as such, and because of 
the nature of the problem of snakebites and its corresponding solution.  However, a network of 
Latin American public reference laboratories producers of antivenin, demonstrated the World 
Health Organization and the Neglected Tropical Disease department that snakebites could be 
tackled using the comprehensive and integrated framework of disease control and prevention 
that the NTD department of WHO preached. Although there were multiple laboratories in this 
network, the role of two champion institutions needs to be described in detail: Instituto 
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Clodomiro Picado and Instituto Butantan. Thanks to the work and early research of these 
institutions we can analyze the circumstances under which a successful snakebite control 
program succeeded, setting a regional and global example and precedent for success. Finally, it 
is also important to highlight the early development of the Antivenin Institute of America 
because its history draws attention to other forces that helped trigger snakebite research and 
control strategies in North America. 
Instituto Clodomiro Picado, Costa Rica   
 
The Institute Clodomiro Picado (ICP) is one of the leading institutions in snake 
envenoming research and production of antivenom and technological transfer in the Americas, 
and perhaps the most important Latin American institution that helped shape the movement of 
snakebites onto the NTD portfolio and WHO global health agenda.  
ICP was founded on the 13th of April of 1970 under the governance of the Ministry of 
Health, with Dr. Róger Bolaños as its founding director. Two years later, on June 2nd 1972, it 
was transferred to the jurisdiction of the Faculty of Microbiology of the University of Costa Rica 
and has remained under that institution until present day. However, the true intellectual origins 
of ICP started decades earlier, with the work of visionary scientist Dr. Clodomiro Picado Twight. 
Twight was the first individual who managed to align the goals of a research institution and the 
goals of the ministry of health and its dependencies towards the control of snakebites using an 
integrated approach to envenomation control. We will explore the visionary work of Picado in 
the control and prevention of snakebites before continuing analyzing the role of ICP in more 
current events. 
Clodomiro Picado Twight was born in 1887 in Nicaragua. He moved with his family to 
Costa Rica in 1890, where he obtained his bachelors diploma (current equivalent of secondary 
education) at the “Liceo de Costa Rica” in 1906 (24). “Clorito”, as he is known among Costa 
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Rican scientists, travelled to Paris under the auspice of the congress of Costa Rica. He obtained 
a Diploma in advanced studies of Zoology and Botanics at La Sorbonne in 1909 and 1912, 
respectively, and a Doctorate in Science from the University of Paris in 1913. After this, he 
spent some time at the Pasteur Institute and Institute of Colonial Medicine in Paris (24). Upon 
his return to Costa Rica, Picado was assigned as the head of the San Juan de Dios Hospital in 
Costa Rica, the oldest hospital of the nation. Picado brought back to Costa Rica the rigor of the 
scientific method, as well as new revolutionary concepts in microbiology and immunology, with 
strong influence from European mentors including Raymond Jacques Sabouraud and Elie 
Metchnikoff (13, 25).  
“Clorito” is described by Afonso Trejos Willis, in the foreword of the first volume of 
Picado’s complete memoirs, as a person who has “a particular close of love, not for science or 
for truth, but for the search of truth through science”(26). He thrived on searching for scientific 
truth, focusing his studies on the biology of bromeliad epiphytes, the physiology of aging, thyroid 
physiology, mycology, and of course snakebites.  Picado was an example of a group of early 
twentieth century scientists who were trained in European institutions, and who returned to Latin 
America bringing with them the European institutional model of academic science(27). Costa 
Rica had exited the state of oligarchy that reigned the country between 1849 and 1870 and had 
welcomed liberalism in all aspects of national life. These scientists aimed to modernize the state 
and science was a vehicle to achieve that. As historians of science in Latin America have 
argued, most nations in early twentieth century underwent a period in which “European 
Positivism” pushed forward the evolution of scientific knowledge. Positivism related to the notion 
that the progress of the nations had been stalled because of colonial rule, offering a framework 
under which economic, industrial and cultural development could move forward. The model of 
European scientific education and scientific institutionalization was the medium under which 
progress could be achieved. Vessuri also argues that under Latin American positivism, new 
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scientific knowledge, “expeditions to the interior and inventories of native flora and fauna were 
seen as effective ways to gain true understanding of a new nations resources and 
possibilities”(27). The work of Clodomiro Picado is a successful example of the goal of the state 
of Costa Rica to move scientific development forward. Picado’s early studies on the nation’s 
epiphytes, as well as snake taxonomy, are examples of this nationalist trend in scientific 
knowledge.  
One of Picado’s main scientific interests was snakebite envenoming. He approached this 
topic from a variety of scientific perspectives, including snake taxonomy, envenoming toxicology 
and pathobiology, immunology, and anti-serum production. He built the first snake house 
(serpentarium) of the San Juan de Dios hospital to further develop his research (13). His 
connection with French scientists was strong, as demonstrated by his collaboration with Pierre 
Poutet from the Institute of Pasteur, who, in Paris, immunized horses with venom from Costa 
Rican snakes for research purposes. Picado described this as an “act of generosity of French 
Sciences and from the Pasteur home”. The long-term objective of this collaboration was to 
provide antiserum with higher specificity and efficacy, in sufficient quantities and for lower 
prices(28). However, the solution to supply of antivenin in Costa Rica, came from a partnership 
between Picado and Instituto Butantan in Sao Paul, Brazil. Thanks to Picado’s knowledge on 
snakes, and to his connection with Viral Brazil director of the Instituto Butantan in Sao Paulo, 
Brazil, antivenin was imported to Costa Rica and successfully used throughout the country, until 
national production initiated in the 1960s. Picado speculated that antivenoms produced at 
Butantan would work with Costa Rican viper envenoming cases because of the distribution and 
taxonomic similarity of snakes throughout Central and South America. This evidence of 
technological transfer between institutions, as well as intergovernmental collaborations between 
two South American governments was the first success story for the control of snakebites. It 
proved that antivenin could be efficiently shipped across borders.  
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One of the key aspects of Picado’s approach to snakebite control was his view of 
snakebites as a complex problem. This meant that Picado understood that there was not a 
single cause, effect, and solution to the problem of snakebite envenomation in Costa Rica, and 
as a result, it required interventions on various fronts: research on venom toxicology, distribution 
of antivenin, health care access and management, training of health care workers to recognize 
and treat cases of envenomation, and a national policy that would encompass these strategies. 
In order to achieve a national snakebite policy of Costa Rica, Picado supported legislation that 
insured the use of antivenoms throughout Costa Rica. On May 24th 1916, the Costa Rica 
congress approved a law that mandated the distribution of antivenin to all main hospitals, police 
stations, railway stations, and plantations. Plantation managers and owners were required to 
have a stock of antivenin in case agricultural workers were bitten, and if the death of a worker 
resulted from the lack of antivenin, the owner was obliged to compensate the family of the victim 
(13, 28).  
Later in 1926, Picado would publish an early version of his most famous treaty on 
snakebite research, “Venomous Snakes of Costa Rica: Their Venoms and Snake Antivenin” 
(Serpientes venenosas de Costa Rica: sus venenos, y seroterapia antiofidica), a publication he 
would complete in 1931. Picado’s later work would focus on other matters such as the 
immunology of aging. His last years of productivity would be spent under the direction of the 
Hygiene Institute in 1940. Some accolades included his inclusion in the Paris Society of Biology 
in 1931 and his naming as “Benefactor of the State” in 1943, a year before his death in 1944.  
Picado’s vision and approach to snakebite control constituted one of the earliest 
examples of an integrated program in Latin America that aimed to tackle a public health 
problem, in a way that mirrored the current goals of the NTD program at WHO. However, 
progress stopped temporarily. Costa Rica went through several decades of political and social 
unrest until the end of the 1950s. The world economic crisis of 1929 and the emergence of 
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socialist parties helped end the thrust provided by the positivism movement. The start of World 
War II, and the civil war of 1948 further delayed endeavors to produce antivenin locally, even 
though the human resources were available. It was not until the early 1960s that snakebite 
research in Costa Rica re-emerged, and the Costa Rican government gained interest in locally 
producing snake antivenin that was specific to the snake population of the country. As a result, 
the “Programa de Sueros Antiofidicos” was created in 1965 by the University of Costa Rica, the 
Embassy of the United States in Costa Rica, and the Costa Rican Ministry of Health. In charge 
of the project was Herschel H. Flowers, a US army veterinarian and expert in snake venom 
toxicology and antivenom production in the US(29). According to Jose Maria Gutierrez, Roger 
Bolano, from the University of Costa Rica, assumed the leadership of the project in junction with 
Flowers, because Jesus Maria Jimenez (expert in snake venom biochemistry) and Flowers 
were unable to work together (30). Polyvalent and anti-coral antivenin was successfully 
produced in 1967. In that same year the National Commission Against Snakebite Envenoming 
(Comisión Nacional contra el Ofidismo) was launched to support and advise the Ministry of 
Public Health with all matters related to snake envenomation control.  The Instituto Clodomiro 
Picado were created three years later in 1970, with Roger Bolanos as head(13).  
The National Commission Against Snakebite Envenoming mirrored the previous 
legislation enacted by the government in 1916 to confront and control the problem of snakebite 
envenomation. This framework was also adopted by ICP. As a result, all major institutions in 
Costa Rica dealing with snakebites shared the same goals and horizontal approach to such a 
complex problem. This is relevant because it proved that complex diseases and public health 
problems (such as snakebite envenomation) could be tackled under this framework at a national 
level. The Ministry of Health, the ICP, the University of Costa Rica, the social security of Costa 
Rica, medical training programs, the primary health network of the country, and social extension 
groups all shared the same goals and philosophy of tackling snakebites under a unified 
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approach. It is this framework that has been working in this Central American country for 
decades that was subsequently mirrored in WHO approach to NTD control.  As a result, the 
experience of Costa Rica provided an example of a success story in snakebite control that could 
be presented to WHO and the NTD strategic advisory group in the form of scientific 
publications, and epidemiologic indicators. 
 
Instituto Butantan, Sao Paulo, Brasil  
 
Insituto Butantan pioneered snakebite control in Latin America and the world. Butantan 
was the product of the Brazilian government drive to institutionalize its response against 
epidemic diseases. Specifically, Bubonic Plague was ravaging Sao Paulo in 1899. As a result, 
the Bacteriological Institute commissioned the creation of the Serum Institute (later called the 
Instituto Butantan) which was officially established on the 23rd of February 1901. Dr. Vital Brazil 
Mineiro da Campanha was assigned as its founding director by Dr. Adolpho Lutz, the director of 
the Bacteriological Institute. Brazil was a pioneer of snake venom research and antivenin 
production and the Instituto Butantan became the first Latin American institution to produce and 
distribute antivenin to Brazilian population and to its regional partners. 
Brazil was a physician trained in the Faculty of Medicine of Rio de Janeiro, working and 
studying at the same time to support himself and his family. Unlike Picado in Costa Rica his 
early training cannot be traced to European institutions. Nonetheless, Vital was comfortable 
reading the scientific publications of those at the forefront of the microbiologic revolution in 
Europe(31) .  
Vital Brazil’s interest in snakebite research can be traced back to 1895, during his time 
as a private practitioner in rural Botucatu, near Sao Paulo. Botucatu was a largely agricultural 
city at the time, with coffee and cattle farming (31), and as a result of his experience there, Vital 
15 
 
Brazil noticed the different clinical syndromes produced by the bite of different snakes. These 
observations led to Vital’s most prominent discovery: the specificity of snake antivenin. In other 
words, he proved that Calmette’s snake antivenin against Naja venom did not work against 
envenomation with Bothrops or Crotalus venom. This was a turning point in snakebite research 
and control because it meant that the control of snakebite envenomation had to be tailored 
towards the distribution of venomous snakes and the specific incidence of snakebites within 
each country(31, 32). Ironically, this discovery made snakebites look dramatically different from 
other NTDs.  It would take a century for modern inter-governmental organizations to recognize 
this as a strategy towards antivenin production and distribution, and one of the main limitations 
towards a successful control of snake envenomation in various countries. By 1898, Brazil had 
proven his theory by inoculating and treating dogs with different venoms and antivenoms. 
However, it was not until 1901 that he was able to formally finish this work at Butantan and 
publish it at the Revista Medica de Sao Paulo (33). Vitals’ observations were also noted by 
other researchers such as bacteriologist Joseph McFarland, in association with Munford 
Laboratories in the United States(34). As a result of these studies, Brazil produced the first 
polyvalent antivenom against Crotalus and Bothrops species. This achievement is important 
because using an effective antivenin against more than one snake simplified the treatment of 
envenomation in rural areas of the world, reducing the technical requirements for its use. This 
was an important hurdle that was circumvented in the path towards the inclusion of snakebites 
as an NTD. By having antivenin that was efficient against more than one specific snake, the 
production and distribution of antivenin could extend to a group of countries or areas that had a 
shared venomous snake diversity and distribution.  
Interestingly, Vital Brazil’s research and strategy for serum distribution was illustrated by 
a trading mechanism between farmers and the Institute of Butantan. Local farmers would deliver 
snakes to Butantan, and the institute would deliver antivenin in exchange(31). Brazil also made 
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sure that he received the epidemiological and clinical characteristics of each envenomation 
case associated with the snakebites that were delivered to the Institute and that were 
associated with a case of envenomation. It is worth noting here the intricate relationship 
between agricultural production in the city of Sao Paulo and snakebite research. Farmers were 
(and currently are) disproportionately affected by snakebite envenoming due to the nature of 
their work at the human-animal interphase of disease. This is a key characteristic of an NTD. 
This connection is not only associated with local, small-scale faming, it is also associated with 
industrial agricultural endeavors of large-scale corporations. As we will see in a different 
scenario in the United States, the economic effect of snakebite envenomation at agricultural 
plantations made the problem relevant at a national level. For Sao Paulo, it was not only 
agricultural corporations, but also the burden of snake envenomation on subsistence farmers 
what triggered the demand for antivenin. It was ultimately an economic and social problem that 
needed to be addressed. Vital Brazil retired to Rio de Janeiro and founded the Instituto Vital 
Brazil in 1919, but later returned to redirect Butantan between 1924 and 1927. 
Marcelo De Franco and Jorge Kalil describe the history and evolution of Instituto 
Butantan. The first stage was characterized by the life and contributions of Vital Brazil. The 
second period, between 1930 and 1970 was characterized by strong efforts to institutionalize 
scientific research and development in Brazil. This is evidenced by the creation of National 
Council for Scientific and Technological Development and the Foundation of Research Support 
of the State of Sao Paulo (35). However, during this period, Butantan’s administration was 
inefficient, and the institution received little federal funds. The reason for this can be explained 
by Vessuri’s narrative of what she called “The Development Decades” in Latin America(27). 
Vessuri argues that after World War II, Latin America underwent a period of industrial growth at 
the urban centers, and consequentially displaced the importance of agriculture.  
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As a result of this displacement, envenomation by snakebites was also regarded as a 
second -tier problem. This does not mean that Brazilian science halted, on the contrary, it grew 
exponentially, while at the same time the Brazilian government aimed to link industrial and 
economic development with scientific development. This led to the National Immunization 
Program in 1973 which promoted the industrial production of vaccines and serums.  
Large injections of capital into the Butantan Institute followed, facilitating the renovation 
of the institute’s laboratories. With the implementation of the National Program for Self-
Sufficiency in Immunlogicals in 1985, the National Program for Snakebite Control in 1986 which 
its later conversion to the National Program for the Control of Accidents by Venomous Animals 
in 1988, the institutionalization of snakebite envenomation control was completed (36).  
In the Twenty First Century, the Instituto Butantan regained its status as a worldwide 
leader in snakebite research and international collaboration. Along with Instituto Clodomiro 
Picado, the creation of the Latin American network of public laboratories producing antivenin 
was created. With the support of the Pan American Center for Foot and Mouth Disease 
(PANAFTOSA), the network (RELAPA) was created (37). In this network, Butantan was not the 
only Brazilian institute that produced antivenin. Other institutions included the Instituto Vital 
Brazil in Rio de Janeiro, the Center of Production and Research in Immunobiologicals and the 
Ezequiel Dias Foundation (FUNED). Of this network, those with the largest production capacity 
included ICP, Butantan, Instituto Vital Brazil, and Mexico’s Laboratory of Biologicals and 
Reactives, with over 1.2 million doses produced altogether per year. (For further account of this 
regional network of laboratories see the section “South to South Collaboration in the Twenty-
First Century)”. The creation of this network provided a crucial example of inter-institutional 
collaboration and technological transfer between Latin American countries. This would help 
advance the case for including snakebite in WHO agenda.  
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The histories of Instituto Clodomiro Picado and Instituto Butantan help understand why these 
two institutions were key players in the movement of snakebites as a Global Health problem. It 
is important to explore the formation of the Antivenin Institute of America as a way of 
highlighting other forces particular to the North and Latin American context that helped shape 
the response towards snakebite control and trigger national alliances and technological transfer 
programs early on.   
Antivenin Institute of America, United States 
 
The production of snakebite antivenin in the United States introduced new sets of 
interests in snakebite treatment and played an important role in the expansion of antivenin 
production in Latin America. These interests included American agricultural corporations in 
Central America, the expansion of tourism and the increasing role of the US military in tropical 
regions of the globe. It also introduced new private-public partnerships in the production of 
antivenom.  
The history of antivenin production in the United States is strongly associated with 
American agro-industrial endeavors in Central America. The United Fruit Company (now 
Chiquita) had operated in Honduras since 1899, producing bananas for exportation. Their main 
administration and processing buildings were in the Caribbean town of Tela, while an 
experimentation station, called the Lancetilla Agricultural Experimentation Station was located 
5km away from the port. The construction of this station was completed in 1926, and, as Lily 
Pearl Balloffet details in her account “Venomous Company: Snakes and Agribusiness in 
Honduras”, as part of this experimentation station, the company built a serpentarium (38). 
Herbert C. Clark, a pathologist and former director of the Gorgas Memorial Laboratory in 
Panama (who was also associated with the United Fruit Co), narrates how the interest in snake 
research resulted from a financial “stimulus” awarded by Dr. William Edgar Decks, the manager 
of the medical department of the United Fruit Co., in 1924 (39, 40). Snakebite envenomation 
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was a problem in the fields of the United Fruit Co, incapacitating and causing the death of 
plantation workers. This stimulus led to the collaboration between Dr. Afranio Pompilio Do 
Amaral, a researcher from Instituto Butantan who had transferred to Harvard University in 1922, 
Dr. Thomas Barbour of the Museum of Comparative Zoology at Harvard University, Mr. Arthur 
Loveridge of the British Museum and Prof. E.R. Dun of Haveford College(32, 41). The goal of 
the project was to complete a snake census of Central America and Colombia, and both snakes 
and venom were shipped to the newly established Antivenin Institute of America. The Antivenin 
Institute of America was established as a coalition of institutions and as subdivision of Mulford 
Biologicals Laboratory, the first institution to produce antivenin in the United States in 1927, at 
least 26 years after Instituto Butantan in Brazil. The institute was directed by Do Amaral, who 
facilitated technological transfers between Brazil and the United States, and cultivated the  
Antivenin Institute of America relationship with Butantan and other Central American countries1 
(32, 41).  
Besides agribusiness one of the main drivers in snakebite research and control, was 
military interventions in tropical regions of the globe, including Latin America. The US – Brazilian 
relationship with respect to antivenin production was initiated by President Theodore Roosevelt, 
who visited Vital Brazil at Instituto Butantan in 1909, asking for antivenin for the troops who 
were after Jose Doroteo Arango Arambula, also known as “Pancho Villa”. Later in 1915, Brazil 
visited Carnegie Mellon University, as well as the National Zoological Park in New York (42). 
Snakebites were later perceived as a problem for US troops fighting in Southeast Asia during 
the 1960s and 70s, and in parts of Latin America during the 1980s. 
Finally, the dawn of the tourism industry also played an important role in highlighting the 
problem of snakebites. Before the production of antivenin in North America by Mulford 
 
1 An interesting detail is that, according to a Times article published in August 1926, in his trip to Harvard University, 
where he was set to give a lecture at Harvard University, Do Amaral brought with him 40 South American snakes as 
a gift to herpetologist Dr. Raymond Lee Ditmars the curator of reptiles at the New York Zoological Park at the time. 
20 
 
Laboratories, the United States imported antivenin form Instituto Butantan and Institute Pasteur 
in France. However, the demand of the nation was growing and could no longer be met by is 
commercial partners. With the commercialization of automobiles and the work benefit of paid 
vacation, any middle-class member of society could afford a vacation trip. As a result internal 
tourism in the USA was growing exponentially. The creation of National Parks by Woodrow 
Wilson in 1916 expanded tourism to wilderness areas of the US, fading the line that separated 
human and snake habitats(39, 43). For example, visits to the Yellowstone National Park 
increased from 30,000 to more than 400,000 between 1916 and 1936.  As a result of their 
explorations into the American’s backyards, people were increasingly “snake conscious” 
increasing the demand for antivenom. 
Late Twentieth Century Stagnation 
Progress made by individual laboratories in Latin America and the world by the mid of 
the twentieth century helped paved the way for snakebites inclusion in the global agenda in the 
twenty first century. It could be argued that the road to inclusion would have been shortened if it 
wasn’t for a period of stagnation between the 1970s and the turn of the century. During this 
period global progress on epidemiological research, antivenin production and snakebite control 
languished.  
The WHO Coordination Meeting on Venoms and Antivenoms was held in Zurich 
Switzerland between the 24 and the 27 of September of 1979. In this meeting, it was 
recommended that more data should be collected on the epidemiology of snakebites as well as 
on effective therapy (44). A list of laboratories producing snake antivenin was provided, which 
included 16 laboratories in Asia, 2 in Africa, 7 in Europe, 8 in Central and South America, 3 in 
North America and 1 in Australia. The resources for global partnerships were there, yet the 
political will and technological capabilities were absent. Only 5 institutions tentatively agreed to 
produce international standard antivenin: Instituto Clodomiro Picado in Costa Rica, Institute of 
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Hygiene in Mexico, Commonwealth Serum Laboratories in Austrialia, Razi State Vaccine and 
Serum Institute in Teheran, Iran, and the Chemo-Sero-Therapeutic Research Institute in Japan. 
It is impressive that given the early stages of worldwide collaboration in antivenin production, 
two of the 5 institutes were in the Americas, with Costa and Rica (with Roger Bolanos as 
director of the ICP as its representative) and Mexico (with J. Fernandez de Castro from the 
Institute of Virology in Mexico D.F. as its representative) as early representatives of the regional 
efforts towards tackling the issue of snakebite envenoming. These were the two only Latin 
American representatives in the meeting, and the reason for the absence of Instituto Butantan 
needs to be further investigated. Other representatives from developing areas of the world with 
high incidence of snakebites included Ghana, Iran, and Thailand. The remainder were multiple 
representatives from the United States, England, Czechoslovakia, Germany, Japan and WHO 
representatives from Switzerland. It is worth noting that the University of Liverpool was also 
represented in this meeting.  Liverpool would take a leading role in future worldwide 
collaboration. At this early stage, the role of Latin American institution was recognized and 
acknowledged by the World Health Organization and by R. David G. Theakston (now Professor 
at the University of Liverpool). However, there was still a lack of global consensus of the way 
forward.  
The meeting held in 1979 was the last of the century. For almost 22 years there were no 
global efforts to address this issue, causing a worldwide antivenin crisis. European laboratories 
stopped producing antivenin altogether, South East Asian laboratories were producing for the 
local demand, and the African region was facing an unprecedented problem in antivenin supply 
(45). The South African Institute of Medical research was one of the few providers of antivenin, 
but by 2001 it had been privatized. The cost of production and lack of appropriate antivenin 
were perhaps the two main limitations.  
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The next meeting WHO meeting on the subject (Standardization and Control of 
Antivenoms) was held in 2001 at the Institute of Laboratory of for Biological Standards and 
Controls of the National institute of Biological Standards and Control in Potters Bar, London. 
Worldwide, only 21 laboratories that produced antivenin were recognized in 2001, in contrast to 
the 37 listed in the 1979 meeting. The main reason for the meeting according to Theakston was 
the need to create reference antivenoms with the overarching aim of improving the safety and 
quality of the products, as well as to discuss and provide pathways to target the already 
recognized antivenin crises of Africa and the world. The WHO requirements for antivenoms not 
been updated since 1971. Theakston acknowledged that the candidate reference venom and 
antivenom were lost when the material was transferred between the WHO Laboratory for 
Biological Standards at Copenhagen to the Institute of Laboratory of Biological Standards of the 
National institute of Biological Standards and Control (UK). This was the product of the work of 
over 13 laboratories worldwide, and the loss of valuable biologic material was a strong 
indication of the lack of interest by intergovernmental institutions on the problem of snakebites. 
By 2001, only one international standard existed and this one dated by to 1964. Acknowledging 
this, however, was a major remediation step forward. 
The three most important recommendations from this meeting were 1) the 
encouragement of international collaboration and 2) the need for national and regional 
standards, rather than a unique international one and 3) the urgent need for treatment 
guidelines. Laboratories with established antivenin production should collaborate with Africa 
nations to produce specific antivenin. These recommendations envisioned and cemented the 
way for what would be to be future South-to-South technological transfer working groups and 
collaborations. All four laboratories who offered to collaborate were Latin American: ICP in 
Costa Rica, Instituto Butantan in Brazil, Instituto Bioclon in Mexico and Instituto Nacional de 
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Salud in Colombia. Once again it is worth highlighting the continued interest to collaborate by 




South to South Cooperation in the Twenty First Century 
The idleness experienced at the end of the twentieth century with regards to snake 
envenomation control was surmounted by the development of new collaborative efforts in Latin 
America during the first decade of the twenty first century.  
South to South cooperation on the snakebite diagnosis, treatment and control was 
clearly delineated by a project funded in 2006 by the Iberomerican Program of Science and 
Technology for Development (Programa Iberoamericano de Ciencia y Tecnologia para el 
Desarrollo) or CYTED for its acronym in Spanish. The title of the project was “Antivenom in 
Iberoamerica: Strengthening of technologies for production and quality control in regional public 
laboratories” (Project 206AC0281) with Dr. Jose Maria Gutierrez, from Instituto Clodomiro 
Picado as principal investigator(47). Its objective was to develop a collaborative effort between 
Latin American laboratories to improve the production and quality of antivenin in the region. 
Additionally, it aimed to enhance capacity building and technology transfer, as well as to serve 
as a call to action to PAHO and WHO to include snakebites in the regional and global Public 
Health agenda. The project included fourteen public institutions from Argentina, Brazil, Bolivia, 
Costa Rica, Colombia, Ecuador, Mexico, Panama and Peru (48). As a result of this project, 
three workshops were organized: the first at Instituto Butantan in Sao Paulo Brazil (June 12-16, 
2006), the second at Instituto Clodomiro Picado, and the third also at Instituto Clodomiro Picado 
(September 16-19 2008). The first meeting had three main objectives: to individually understand 
and compare the situations of each public laboratory in the region with respect to snakebite 
epidemiology, antivenin production and demand, and to establish ways in which technological 
transfer, capacity building and cooperative strategies could be met (48). Thanks to the 
participation of all laboratory representatives, it was found that huge differences existed with 
respect to available production technologies and consequentially, quality of antivenin. It was 
also noted that deficiencies were a direct result of lack of technological training, and national 
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governmental support. It is notable that the difference in antivenin production and technology 
were strongly associated with snakebite and antivenin production and distribution policies in the 
region. Those with the highest capacity to produce antivenin and distribute to the region were 
Costa Rica and Brazil who have the longest history of research and development, as well as the 
most robust policies to tackle the issue at hand. The meeting called governments of those 
countries lacking in both policy and economic support to work together with the more 
experienced countries to ramp up regional capacity. Additionally, the meeting also demanded 
strong involvement from intergovernmental agencies such as PAHO and WHO, with specific 
aims such as the creation of regional and global guidelines on snakebite diagnosis, treatment, 
and control(49).  
These Latin American interactions and collaborations efforts created a community of 
researchers and institutions, in which the need for global advocacy for the control of snakebites 
was highlighted. The meetings underscored the urgency of international collaboration at national 
and regional levels and emphasized the need for public-private relationships that were able to 
gather epidemiological information on the problem and delineate targeted interventions. It also 
pushed for effective and safe antivenin that was locally produced, economically accessible and 
technologically feasible (50). In-person meetings, scientific sessions and discussions sparked 
the institutional and political will of Latin American nations to push and present the problem of 
snakebites to the WHO department of NTDs. These South-to-South interchanges of ideas, 
problems and solutions played a critical role in the acceptance of snakebites as a global health 
problem. Without this synchronous international push from Latin America, it is probable that 
movement that placed snakebites in the NTD portfolio would have lost significant drive and 




From Costa Rica to the World  
Inter-institutional collaborations and private-private partnerships that aimed to reduce the 
burden of snakebites rapidly increased in the twenty first century as a result of the WHO 
meeting at London in 2001. These stories of international collaboration and technological 
transfer were important because they helped built international and institutional diplomacy that 
was required to push forward the need to address the problem snakebites, globally. Through 
institutional, commercial and public-private alliances, countries in the Global South were able to 
align their requirements and advocate for the cause at the World Health Organization.  
The first of these examples was the EchiTAb Study Group. This group was initiated in 
2003 as a collaboration between academic institutions in the United Kingdom (Oxford University 
and Liverpool School of Tropical Medicine), the Nigerian government, public institutions of Latin 
America (INS Colombia and ICP Costa Rica) as well as private industry (Micropharm in the 
UK)(13). The Nigerian government was facing an enormous rate of snakebite envenoming 
(170/100,000 individuals, 2006 census) and yet they had no regional production strategy, 
capacity building and training program, or management strategy. The majority of cases were 
occurring in areas of the country where agricultural production took place, especially during 
planting and harvesting periods, a pattern that is also encountered in other regions of the world 
and in earlier examples of snakebite control. The country had been importing antivenin from 
India, but had encountered a variety of problems, such as inadequate type of antivenin for the 
species of snake, high cost, early expiration rates, and problems related to delivery of the 
product (such as dose, instructions, and presentation format). Overall, the main hurdle was 
financial. Antivenin available for the country was expensive and inadequate.  
The creation of this collaboration was perhaps a direct result of the involvement of R. 
David Theakston. Theakston studied parasitology in Nigeria between 1972 and 1974, and 
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afterwards collaborated with H. Alistair Reid from the London School of Hygiene and Tropical 
Medicine. He became the head of the Alistair Read Venom Research Unit and collaborated 
early on with WHO as detailed previously. Data produced by this collaboration enabled the 
production of antivenin (EchiTAb-Plus-ICP) at the ICP in Costa Rica that was specifically 
tailored for the needs of Nigeria. The product was successfully tested in phase III randomized 
clinical trials and is now being distributed in Nigeria, Mali, Burkina Faso, Benin, Central African 
Republic and South Sudan with the help of Medicins sans Frontiers (MSF) 
 A second success story that needs to be highlighted was the collaboration between 
Costa Rica (ICP), Papua New Guinea (PNG) and NHMRC funded Australian Venom Research 
Unit (AVRU) associated with the University of Melbourne, for the production and distribution of 
antivenin tailored to the needs of PNG. PNG relied on expensive antivenins produced in 
Australia whose production output was unsustainable for the needs of PNG. As a result, project 
funded by the AVRU and the University of Papua New Guinea aim to create a serpentarium for 
the collection of venom, which was shipped to the University of Melbourne for lyophilization and 
later transport to ICP for horse immunization and antivenin production(51). The output of this 
collaboration was a Phase I/ Phase II randomized controlled trial to test the safety and minimum 
dose effectiveness of a new monovalent antivenom for the bite of taipan snakes in PNG started 
in 2012. The antivenin was produced at ICP, the trial was sponsored by the University of 
Melbourne and operationalized at PNG with the collaboration of the University of Papua New 
Guinea.  
Finally, it is important to highlight the latest partnership between ICP, the Animal Venom 
Research International (AVRI), and NGO from the United States and the University of 
Peradeniya in Sri Lanka. It is estimated that more than 30,000 cases of snakebite envenomation 
occur per year in Sri Lanka, resulting in at least 400 deaths. The objective of this collaboration 
was to develop a new antivenom against the most important Sri Lankan snakes, initiate 
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production at ICP and then complete the technological transfer to accomplish cost-effective 
local antivenom production(52, 53). It is essentially the same model of collaboration evidenced 
in the two previous examples of ICP international partnerships with other low- and middle-
income countries but with a crucial difference. This is the first public institutional partnership with 
a nonprofit organization (AVRI), and the exclusion of an academic entity from Europe and the 
United States, highlighting the degree of international confidence that the ICP has gathered. 
The role of AVRI is described as in charge of developing a collaboration network with health 
care professionals in Sri Lanka with the objectives of understanding the attitudes, needs and 
limitations with respect to snakebite control. AVRI also coordinated the creation of the 
serpentarium at the University of Peradeniya, and worked in training local experts in snake 
handling and venom extraction with the collaboration of the Kentucky Reptile Zoo in the United 
States (52). The major limitation of this public-private partnership was the lack of hard money 
that ensured the constant supply and efficient technological transfer. That said, the production 
of antivenin at the local level in Sri Lanka will ultimately depend on the political will of its 
government.  
As a result of Costa Rica’s contribution to the control of snakebites, the World Health 
Assembly awarded ICP in 2011, the Public Health Award in memoriam of Dr. Lee Jong-Wook. 
Yamillet Angulo, the director ICP received the award. As Sylvia Poll, a former athlete and 
representative of Costa Rica during that meeting in Geneva, said, the World Health 
Organization was looking at Costa Rica as a role model. It is this model of success that was 
presented as a specific case study for the adoption of snakebites as an NTD in 2017. Without 
these examples of technological transfer success stories, would the NTD strategic advisory 
group have included snakebites in its portfolio? The experience and knowledge gained by the 
network of Latin American institutions, as well as the growing international collaboration efforts 
contributed to a global consensus that there was an urgent need to address the problem of 
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snakebites. Without these efforts, it is unlikely that the case of snakebites as an NTD would 




The Final Step: Global Advocacy for Snakebites  
After the WHO meeting held in London in 2001 (Standardization and Control of 
Antivenoms), the next big step related to global snakebite advocacy was the WHO meeting held 
at the department of Medicines Policy and Standards, Health Technology and Pharmaceuticals 
at Geneva in January 2007. The meeting’s principal objective was to discuss sustainable 
mechanisms that would ensure the production of sufficient snake antivenin and rabies antisera, 
and to “identify and bring together existing and potential partners”. It is interesting that in this 
meeting WHO jointly targeted rabies and snakebites, classifying both of these diseases as 
neglected. In fact, the report that produced from this meeting was titled “Rabies and 
Envenoming: A Neglected Public Health Issue” (54). By 2007, conversations had already 
happened and the decision to move forward the case of snakebites as a WHO NTD had been 
made. It is interesting how this WHO publication led researchers and snakebite advocacy actors 
to consider the snakebites already as an NTD. However, under official guidelines of WHO, it 
was still not included in the NTD portfolio. 
Moreover, if we consider both rabies and snakebites as contenders in the race of 
inclusion into the NTD group, rabies had key logistical advantages. First, there was a universal 
rabies antiserum that worked against all dog bites, and there was a dog vaccine that would also 
contribute to rabies control campaigns that had sufficient and integrated support from the 
Ministry of Health and the national institution in charge of animal welfare and zoonotic diseases. 
Snakebites, on the contrary, as we have explained before, need an antivenin that is tailored 
towards the venomous snake distribution of each country, and there is no additional 
pharmacological tool that can help. That said, similar limitations related to the commercialization 
and distribution of biologicals were identified, and these applied to both rabies antiserum and 
snake antivenin. One of the most important was the vulnerability of the biological product to 
fluctuations in price. An example of such is the increase in price of snake antivenin from India 
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($10) to Papua New Guinea ($940)(55). Even though snake antivenin was being produced in a 
low-income nation, prices were sky-rocketing at the receiver end, prohibiting the purchase of 
enough product to supply the demand of the country. Additionally, the lack of laboratories with 
Good Manufacturing Practices certification (a requirement by WHO) would cause a huge loss of 
production if laboratories were not able to upgrade. Participants of this meeting included 
representatives from private and public institutions, industry (such as Sanofi Pasteur) and 
academia of Latin America (Mexico, Costa Rica, Brazil, Bolivia), North America (Canada and 
the US), Europe (France, United Kingdom, Croatia), Africa (Morocco, Nigeria), Asia (India, 
Vietnam, Nepal, Japan, Sri Lanka, China), and non-governmental organizations such as Red 
Cross and United Nations Children’s Fund. The conclusion of this meeting was that WHO 
should lead an initiative that enabled access to antiserum and antivenin, and that its main 
mechanism of achieving this was facilitating technological transfer between countries, a model 
that had been pioneered by Latin American countries.  
 An advocacy paper written by Jose Maria Gutierrez from ICP, Hui Wen Fan from 
Instituto Butantan, David A. Warrel from the University of Oxford UK, and David Williams from 
the University of Melbourne, Australia in 2010 was a re-visitation of this 2007 meeting arguing 
that there was still a large pathway to cover. Interestingly, they presented the issue as a 
neglected “environmental and occupational disease” of global concern, stating that it affected 
almost exclusively “poor and politically unempowered people” living in the Global South (50). 
Shortly after, the WHO Guidelines for the Production, Control and Regulation of Snake 
Antivenom Immunoglobulins were finally published, three years after the 2007 meeting in which 
they were promised (WHO, 2010). A second advocacy paper by similar authors was published 
in 2010 in the journal PLoS NTDS(56). Jose Maria Gutierrez argued that although the initiatives 
that we have mentioned had been an important step forward in the global fight against snake 
envenomation, progress had been hindered by the focus of the NDT department on the control 
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of helminths. This claim was controversial because it underscored the overall rivalry of working 
groups handling different NTD diseases and competing for financial support and overall visibility 
within the department. It also highlighted that the WHO NTD department continued to focus on 
parasitic diseases that easily fit the definition of a neglected disease.  
A further push that helped launch snakebites into the NTD portfolio was the involvement 
of non-governmental institutions, such as the Global Snakebites Initiative. This was an 
interinstitutional and interdisciplinary working group whose main objective was to come up with 
easy and budget conscious solutions to the global problem of snakebites(57). It was funded in 
2008 after a conference in the University of Melbourne, Australia, by members of academia, 
non-governmental organizations, industry representatives, government representatives and 
grassroots organizations. Since its creation it has with fundraising and creating liaisons between 
institutions that reliably produce antivenin and countries that need them. For instance, the 
AntivenomAID is a project that aims to produce a Pan-African polyvalent antivenom. The GSI is 
currently directed by Dr. David Williams, a professor from the University of Melbourne and a 
pioneering in enabling intercontinental collaborations and technological transfer of antivenin 
production between Costa Rica, Australia and Papua New Guinea. Williams is also the head of 
the Australian Venom Research Unit at the University of Melbourne, an institution that has been 
concurrently advocating for the official inclusion of snakebites into the NTD portfolio as a 
representative from the Australian academia. Williams would later chair between 2017 and 2019 
the WHO Working Group on Snakebite Envenoming. 
The case for WHO inclusion of snakebites in NTDs was further advanced by UNICEF’s 
World Report on Child Injury Prevention in 2008 in which snakebites were considered an 
important cause of child injury and death. Snakebites were grouped with other unintentional 
injuries such as smothering, choking, asphyxiation, other animal bites, hypothermia and 
hyperthermia. This group accounted for 23% of children deaths worldwide(58).   
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Evidence of other regional efforts during the same time include a regional meeting on 
the clinical management of snakebite held in Myanmar in December 2009, and the subsequent 
publication of the guidelines for the management of snakebites by the South East Asia office 
and the African Office in 2010 (59-61). These publications served as evidence that the topic of 
snakebites was already being independently assessed by other inter-governmental institutions 
such as UNICEF, and in other WHO regional offices. The snakebite momentum was now global, 
constant and synchronous.   
As a result, on June 2017, the “Recommendation for the Adoption of an Additional 
Disease as a Neglected Tropical Disease (category A) – The case of Snakebite Envenoming” 
sponsored by Costa Rica on January 2017 and co-sponsored by Angola, Benin, Brazil, 
Cameroon, Chad, Colombia, Costa Rica, Ecuador, Honduras, Guatemala, Mexico, Namibia, 
The Netherlands, Pakistan, Panama, Philippines, Peru, Uganda, was adopted. The resolution to 
adopt the global framework to address the problem of global snakebite envenomation was 
passed on the 71st World Assembly, on May 24, 2018 (3, 4). Snakebites had finally climbed its 
way up to the pinnacle of the global NTD agenda and could now take part of global coordination 
efforts that addressed its burden. Since the WHO has since created Working Group on 
Snakebite Envenoming and has already published the strategy for prevention and control 
published in 2019 (62) as well as  guidelines for establishing a poison center in 2020 (63).  
The interest of the Wellcome Trust in snakebite research can be observed as a 
response to the inclusion of snakebites into the NTD agenda, and the associated renewed 
interest in the problem. Wellcome Tust launched a grant scheme only for snakebites called 
“Snakebite Grants: Discovering and Developing New Treatments”. It has since funded 7 
institutions, six of which are located in the United Kingdom and Denmark, with the exception of 
one institution in Tunisia. Although this funding mechanism is definitely an enthusiastic support, 
time will only tell of these types of academic funding mechanism will help advance the 
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Snakebite Research in Latin America: Excellence in Science at the Periphery 
The study of Latin American biomedical science is quite new if we compare it to the work 
done to explore and explain the history of this discipline in Europe (and to some extent North 
America). Published work is mainly represented by the efforts of historians that have tried to 
study the developments of Latin American science through the lens of the ongoing political and 
sociocultural movements of the region and individual countries, and not as the continuity of 
European science. To frame the history of science in Latin America, historians have used the 
term “peripheral science”. This concept was borrowed from the Theory of Dependance, which 
describes how resources from poor developing countries are transferred to wealthy 
industrialized nations. This theory has been used to explain the reasons for the 
underdevelopment of Latin American societies. When applied to the study of the history of 
biomedical science and medicine in Latin America, it serves as a framework to explain how 
scientific developments took place in areas of the world that are not industrialized and are 
essentially behind the technological achievements of the centers of science and technology in 
the world. It is used both to describe the geographic location of these countries with respect to 
the worldwide scientific hubs, as well as the quality of the scientific output and its researchers.  
However, some historians, such as Marcos Cueto, have used the term “science at the 
periphery”, to describe the scientific developments that took place at these geographic locations 
without the inherent bias or categorization that the science performed was inferior with respect 
to the industrialized counterpart. Cueto argues that the development of biomedical science at 
these peripheral countries took place under their own rules and framework and that it must be 
analyzed within each specific cultural, social and political context. (5). Cueto goes one step 
further and provides evidence that there can be scientific “excellence” at these peripheral hubs.  
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The early scientific endeavors and successes of Clodomiro Picado and Vital Brazil, the 
consequential success of the control program of the Instituto Clodomiro Picado and Instituto 
Butantan (with respect to antivenin production and technological transfer), are examples of 
excellence in science at the periphery. The outcomes of their research, outreach programs and 
international collaboration are an example of multiple hubs of scientific development done at 
peripheral cities that represent achievements at a global scale. Costa Rica and Brazil’s 
excellence caused the union of multiple peripheral scientific hubs, ultimately changing the 
course of history of a disease.  
 The reason why science at these specific peripheral hubs worked was perhaps 
associated with other forces that were driving scientific development at each specific country. 
The main explanation is probably related to the financial and (as a result) political interest of the 
nations in which the incidence of snakebites was high. At hubs such as Sao Paulo and San 
Jose de Costa Rica, the role of agribusiness in the country’s economy and the role of the 
subsistence farmer in society served as agents of change with respect to snakebite control. To 
these peripheries, snakebite was a central problem at specific points in history, and early 
progress cemented the way for successful frameworks and control programs.  
 Moreover, the production of a pharmaceutical drug that served to address the problem of 
snakebites is quite unique in the history of Global Health. Traditionally, pharmaceutical 
interventions that are targeted towards neglected tropical diseases, or diseases that 
disproportionately affect the Global South are conceptually and physically created in the Global 
North. That means that pharmaceutical innovation and drug production takes place in 
industrialized nations, while the countries that need these drugs are the recipients. The 
solutions (objects) to a public health problem are transferred from north to south (64). However, 
in the case of snake antivenin, pharmaceutical knowledge is being created at the south and for 
the south. According to Anne Pollock, a professor of Global Health and Social Medicine at Kings 
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College, the place where pharmaceutical knowledge AND product is being developed matters, 
because the entire production process represent the public health needs of the nation. In other 
words, the production of antivenin at developing nations that have the highest incidence of 
snakebites, represents the fulfillment of the nation’s priorities.  
 Through the regional and international collaborative efforts, and the technological 
transfer of antivenin production, helped multiple hubs of local knowledge have emerged. These 
hubs have been able to form a coalition that bridges the entire hemisphere, allowing peripheral 
hubs of science to participate and steer the global health by pushing the science of snakebites 




Upcoming Challenges  
The addition of snakebites into the WHO NTD portfolio does not guarantee the success of 
the global prevention and control program, or the production and supply of antivenin to the 
areas of the world where it is needed the most.  This is because of the biological and logistical 
nature of the problem of snakebites, and their inherent differences with the rest of the diseases 
that the NTD department manages.  
As described previously, neglected tropical diseases are characterized by being able to be 
controlled and prevented by feasible and easy interventions. WHO identified 5 strategic 
interventions that would, theoretically tackle all NTDs: preventive chemotherapy, intensified 
case-management, vector control, safe water, sanitation and hygiene and veterinary public 
health(23). Of these, perhaps intensified case-management is the single intervention that would 
apply to the problem of snakebites, given that this disease is not preventable by any specific 
chemotherapy, and treatable by quick and easy access to the right antivenom. This was 
highlighted by the strategic advisory group (STAG) on its tenth meeting held on March 2017 in 
Geneva. In fact, STAG members highlighted that the programmatic aspects of handling 
snakebites would not be properly handled under the NTD framework. However, it was resolved 
at the STAG meeting that there were several parallels between the work that the NTD 
department was already performing and the needs to tackle snakebites, such as improved case 
management and access to antivenoms to highly isolated populations, tackling emerging 
problems at the human-animal interphase, partnerships with pharmaceutical industries, similar 
control strategies and immunoglobulin production as those being implemented with rabies 
(already an NTD), the need for an overall “holistic” approach to tackle a complex problem such 
as this one, which is already the framework under which the NTD department aims to handle all 
other NTDs. However, it was stated, that if any additional responsibilities are required for 
snakebites, then additional resources would also be required to address(3).  
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It will be important in the coming years that international collaborations prove their success 
through efficient technological transfer of antivenin production, sustained production and most 
importantly fair and equitable commercialization among countries that have a strong demand for 
the product. The COVID19 pandemic has brought down the momentum that the global 
snakebite movement had gained over the past 3 years. It will depend on the network of 
collaborators and WHO member countries that the roadmap delineated in 2019 is put effectively 
into practice. Only time will tell if snakebites to the global health agenda was have joined the 





The snakebite journey towards becoming a Global Health problem is characterized by 
the development of scientific and pharmacological knowledge in peripheral cities of the Global 
South. A network of Latin American public laboratories led by two champion institutions helped 
catapult the snakebites as a neglected tropical disease. It proved that scientific hubs in the 
peripheries are able to not only produce new knowledge, but also appropriate solutions to a 
global health problem, by South to the South collaborations. These solutions are not only 
composed of a pharmacological object (antivenin), but also of an integrated approach to 
disease control. With successful experiences in snakebite control, these peripheral cities were 
able to export their framework of snake control to other peripheral cities afflicted by high 
incidence of snake envenomation and lack of antivenin supply. This holistic framework mirrored 
the approach taken by the NTD department on other neglected parasitic diseases. A regional 
movement gained momentum and expanded into what would become a movement of the 
Global South characterized by collaborations between public and private institutions, academic 
research groups, non-governmental organizations and pharmaceutical companies. This 
peripheral movement transformed into a central movement, and ultimately achieved the goal of 
placing snakebites in the Global Health agenda of the twenty first century. The overall success 
of this achievement will continue to depend on the production of basic and implementation 
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